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Abstract
This review focuses key advances in different pediatric fields that were published in Italian Journal of Pediatrics and in
international journals in 2015. Weaning studies continue to show promise for preventing food allergy. New diagnostic
tools are available for identifying the allergic origin of allergic-like symptoms. Advances have been reported in obesity,
short stature and autoimmune endocrine disorders. New molecules are offered to reduce weight gain and insulin-
resistance in obese children. Regional investigations may provide suggestions for preventing short stature.
Epidemiological studies have evidenced the high incidence of Graves’ disease and Hashimoto’s thyroiditis in patients
with Down syndrome. Documentation of novel risk factors for celiac disease are of use to develop strategies for
prevention in the population at-risk. Diagnostic criteria for non-celiac gluten sensitivity have been reported. Negative
effect on nervous system development of the supernumerary X chromosome in Klinefelter syndrome has emerged.
Improvements have been made in understanding rare diseases such as Rubinstein-Taybi syndrome. Eltrombopag is an
effective therapy for immune trombocytopenia. Children with sickle-cell anemia are at risk for nocturnal enuresis.
Invasive diseases caused by Streptococcus pyogenes are still common despite of vaccination. No difference in frequency
of antibiotic prescriptions for acute otitis media between before the publication of the national guideline and after has
been found. The importance of timing of iron administration in low birth weight infants, the effect of probiotics for
preventing necrotising enterocolitis and perspectives for managing jaundice and cholestasis in neonates have been
highlighted. New strategies have been developed to reduce the risk for relapse in nephrotic syndrome including
prednisolone during upper respiratory infection. Insights into the pathophysiology of cerebral palsy, arterial ischemic
stroke and acute encephalitis may drive advances in treatment. Recommendations on breastfeeding and
complementary feeding have been updated. Novel treatments for rhabdomyosarcoma should be considered for
paediatric patients. Control of risk factors for bronchiolitis and administration of pavilizumab for preventing respiratory
syncytial virus infection may reduce hospitalization. Identification of risk factors for hospitalization in children with
wheezing can improve the management of this disease. Deletions or mutations in genes encoding proteins for
surfactant function may cause diffuse lung disease.
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Background
This review highlights main advances in allergy, endocrin-
ology, gastroenterology, genetics, haematology, infectious
diseases, neonatology, nephrology, neurology, nutrition,
oncology and pulmonology in childhood. Papers were pri-
marily selected from the most accessed articles published




Food allergy is a frequent public health complaint [1–3]
with potentially life threatening reactions. Several observa-
tional studies have suggested that early introduction of
certain solid foods in infants may be associated with a de-
cline of food allergy. Interventional studies were devel-
oped to more definitively ascertain these outcomes. In
infants with atopic eczema, egg introduction at 4 months
resulted in a nonsignificant lower rate of egg allergy at
12 months of age in comparison with a control group who
went on egg-free diet [2]. Du Toit et al. [1] introduced
peanut at a median age of 7.8 months, in children at risk
for peanut allergy because of atopic eczema o egg
sensitization. They found that peanut consumption was
effective in reducing the prevalence of peanut allergy both
in children who were not sensitized to peanuts (primary
prevention) and in those who were sensitized (secondary
prevention) in comparison with controls. Consequently, a
consensus communication [4] recommended early intro-
duction of peanut to prevent peanut allergy in children at
risk. However, the term early seems to be inappropriate
and it may be misinterpreted, since findings by Du Toit
et al. [1] do not imply that current weaning plan should
be modified [5]. Findings of interventional studies on in-
ducing food tolerance by the oral route raise the question
whether cutaneous exposure to large amounts of food al-
lergens [6] or inhalation of food particles [7] may be also
used to prevent food allergy.
In the pediatric population, allergic-like symptoms are
one of the most common causes for consultation in a
primary care setting. Oral food challenge remains the
gold standard for diagnosis of food allergy. This happens
also when other concomitant precipitating factors are
required to trigger an allergic reaction [8]. Regarding
other investigations, Caglayan et al. [9] showed that
atopy patch test for the evaluation of egg and cow’s milk
allergy should not be routinely used. Fiocchi et al. [10]
aimed to clarify the sensitization rate in children with
common allergic symptoms. They determined serum
specific IgE levels to foods and inhalants in 532 children
(<15 years of age) with at least one allergy-like symptom,
from 21 primary care centers in two geographic areas of
Italy and Spain. They found 267 (50.2 %) atopic children
with at least one positive serum specific IgE antibody.
Multiple sensitizations were common: 14 were mono-
sensitized, 37 were sensitized to 2–3 allergens and 49 %
to more than 3 allergens. This point out that molecular
diagnosis would be often necessary to distinguish be-
tween polysensitized children who are sensitized to
genuine allergens and those sensitized to cross-reactive
allergens [11]. The average number of symptoms in the
atopic group was 3.3 vs 2.8 in the non-atopic group. The
prevalence of sensitization to single allergens was high-
est for grass, ragweed and house-dust mites (19–28) and
among tree allergens was for olive trees (16.5 %). Cow’s
milk and egg white were the most sensitizing foods.
Food allergen sensitization predominated in younger
children whereas the inverse occurred with inhalant al-
lergens. A significant positive correlation between pa-
tient age and number of sensitizations was found. This
study highlights that more specific means than symp-
toms alone, are needed to reduce unnecessary specific
IgE measurement in primary care. However, it should be
also taken into account that when measurement of
serum specific IgE levels and not skin prick tests to aller-
gen extracts are performed, some allergic sensitizations
may be missed. Along this line, it has been recently
shown that this happens also with molecular allergens.
Asero et al. [12] found that results of specific IgE to Phl
p 12 (grass profilin) and skin prick tests to natural profi-
lin (Pho d 2), purified from date palm extract gave a
concordant response in 91 % of cases. In asthmatic pa-
tients, exhaled breath biomarkers [13] may be useful for
identifying allergic patients. Among them fractional
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exhaled nitric oxide (FeNO) is significantly correlated
with specific IgE antibodies levels to house dust mite in
atopic asthmatic patients [14]. Furthermore, FeNO
values greater that 21 ppb are associated with airway
eosinophilia in corticosteroid-naïve patients [15] and are
helpful in predicting loss of asthma control [16]. It has
been found increased levels of oxidative stress markers
such as pH [17] and hydrogen peroxide [18], that are
sometimes related to decrease lung function in
asthmatics. Hydrogen peroxide induces apoptosis of eo-
sinophils and enhances the resolution of allergic inflam-
mation [19]. Longitudinal studies are warranted to
establish whether such markers may be helpful in diag-
nosis and control of asthma. Exercise induced broncho-
constriction (EIB) is commonly experienced by
asthmatic children. Johansson et al. [20] showed that the
prevalence of EIB was 19.2 % in a general population of
adolescents and 42.4 %. In subjects with exercise-
induced dyspnea, less than 50 % of subjects with EIB
had ever had asthma. In agreement, it has been shown
that EIB is a feature of not only of asthma but also of al-
lergic rhinitis and atopic eczema [21]. Furthermore,
10.8 % of subjects with exercise-induced dyspnea pre-
sented exercise-induced laryngeal obstruction. This can
be an important differential diagnosis in adolescents
breathing problems during exercise [20].
Endocrinology
Advances have been reported in obesity, short stature and
autoimmune endocrine disorders. Childhood obesity and
overweight have increased worldwide during the last de-
cades. Lobstein et al. [22] highlight the need for obesity
prevention programme in high-income countries. Com-
prehensive interventions rather than single-component in-
terventions, focused on meals, classroom activities, sports,
and play activities are essential to reverse the obesity
trend. Interventions should be conducted at kindergarten,
school, home, community. Childhood obesity prevention
interventions have been demonstrated to be cost effective.
Another question is how early prevention programme
should start. The NOURISH randomized controlled trial
[23] showed that in infancy, complementary feeding prac-
tices promoting self-regulation of intake and preference of
healthy foods had effects that were sustained up to 5 years
of age. However, no effect was noted for anthropometric
measures or the prevalence of overweight/obesity. Obesity
prevention should take into account the industrial interest
in creating overweight [22]. So, regulatory steps should be
taken to protect children from exposure to advertising
that may influence dietary preferences. Specific nutrient
standards for products are required for improving nutri-
tion. Children and adolescents who are obese have risk
factors for cardiovascular disease, prediabetes, bone and
joint problems, sleep apnea, and social and psychological
problems and to be obese as adults. Little is known
whether there are subgroups of obese children who are at
greater risk for developing cardiovascular diseases. Chang
et al. [24] studied lipid profile, insulin, glucose, leptin and
circulating levels of inflammatory markers, such as tumor
necrosis factor-α, interleukin-6, monocyte chemoattract-
ant protein-1, and the high-sensitive C-reactive protein, in
male children, 19 obese, 10 overweight and 16 controls.
Obese and overweight subjects had insulin resistance, sig-
nificant higher inflammatory cytokine levels including
high-sensitive C-reactive protein, PAI-1, tumor necrosis
factor-α and leptin levels. Lipid profile was abnormal only
in obese children. A factor analysis identified three do-
mains that explained 74.08 % of the total variance among
the obese children (factor 1:lipid, factor 2: obesity inflam-
mation, factor 3: insulin sensitivity domains). These
domains might be applied to predict the onset of cardio-
vascular diseases in adulthood. The treatment of child-
hood obesity is time consuming, problematic, and costly.
Two studies addressed the role of various dietary inter-
ventions and physical activity in children. Stagi et al. [25]
assessed the effect of various treatments on body mass
index (BMI) and basal insulin levels in obese children and
adolescents with family history of obesity and type 2 dia-
betes mellitus (T2DM). In a randomised study, 133 chil-
dren were divided into three arms. Arm A was treated
with low glycaemic index diet and new complex of poly-
saccharidic macromolecules (cellulose, hemicellulose, pec-
tin, mucilages) that slows down the rate of carbohydrate
and fat absorption. Arm B was treated with low glycaemic
index diet diet and Arm C treated with energy restricted
diets. After 1 year, BMI reduction was significant in indi-
viduals subjected to low glycaemic index diet but not to
energy restricted diets diet. Furthermore, Arm A subjects
have significantly reduced BMI-SDSs compared to
Arm B and Arm C subjects. Insulin and glucose
levels were significantly reduced in Arm A, whereas
in Arm B, we observed a significant reduction in in-
sulin but not in glucose levels. In Arm C, insulin and
glucose levels did not differ from baseline. The bene-
fit of a complex of polysaccharidic macromolecules
(cellulose, hemicellulose, pectin, mucilages) added to
low glycaemic index diet should be confirmed with
further studies that include larger sample with longer
follow-up.
Verduci et al. [26] evaluated whether a 1-year inter-
vention based on normocaloric diet and physical activity
may impact the BMI status, blood lipid profile and glu-
cose metabolism indicators in 90 obese children. At the
end of intervention, children showed a reduction in BMI
z-score, triglycerides and triglyceride glucose index, and
an increase in HDL cholesterol. Prevalence of insulin re-
sistance declined from 51.8 to 36.5 and prevalence of
metabolic syndrome from 17.1 % to 4.9 %.
Caffarelli et al. Italian Journal of Pediatrics  (2016) 42:75 Page 3 of 17
Several insights on short stature have been reported. Na-
tional studies on the prevalence of short stature are im-
portant. However, the prevalence of short stature may have
significant regional variations in relation to race, climate,
psychosocial problems and malnutrition. Wang et al. [27]
assessed height in 12,009 students aged from 7 to 18 years,
in Anhui province (China). Short stature was defined ac-
cording to the criteria of the Chinese Medical Association
as follows: height under 2SD of average height in same
race, gender and age; height below the third percentile of
average height in same race, gender and age. The preva-
lence of short stature was 3.16 % and it was similar to that
reported in other regions of China. The rate was higher in
rural areas than in urban areas, higher in economically
backward areas than in economically developed areas.
They concluded that a local government plan is needed to
prevent short stature. It should carry out measures such as
health education, reasonable diet, fitting exercise, adequate
sleep and improving life style. Among children with idio-
pathic short stature effective treatment modalities are still
under evaluation. Recombinant growth hormone (rGH) or
insulin-like growth factor-1 (rIGF-1) can be assumed as an
alternative in the treatment of these children. Recently,
rGH has been approved for therapy in idiopathic short
stature but reports on this treatment are limited. Siklar
et al. [28] recruited 21 ISS children of unknown etiology
and with IGF-1 levels below the −2 SDs of normal levels
with the aim of determining short and long-term effects of
rGH treatment. The height of the patients improved from
−3.16 ± 0.46 SD score (SDS) to −1.9 ± 0.66 SDS. At the end
of the follow-up period (5.42 ± 1.67-year), mean height
SDS was −1.72. Almost 40 % of patients reached their tar-
get height. A female preponderance was noted in the re-
sponder group. The rGH treatment was safe.
Response to GH therapy is variable in subjects and de-
pends on individual factors including age, BMI, genetic
and gender. The exon 3-deleted GH receptor (GHRd3) has
been showed to be associated with better growth response
to r-GH treatment in children with idiopathic short stature
and children born small for gestational age. Valsesia et al.
[29] analyzed the clinical and genetic data generated in the
PREDICT study and in the PREDICT long-term follow-up
study to investigate association between GHRd3 and
growth response to r-hGH over 3 years in relation to sever-
ity of GH deficiency. GHRd3 carriers with higher peak GH
level had better growth (C2.7 cm; C0.2 SDS) than those
with low peak GH level. Similar patterns were observed for
GH-dependent biomarkers. Gene expression profiles were
significantly different between groups, indicating that the
interaction between GH status and GHRd3 carriage can be
identified at a transcriptomic level. GH treatment is fre-
quently prescribed in Prader Willi Syndrome (PWS) at
early infancy or childhood and leads to improve changes in
body composition, physical activity and growth velocity.
Butler et al. [30] provided new growth charts of weight,
height, head circumference and BMI for non-GH treated
subject with PWS aged 3 to 18 years to be used in clinical
setting. Anthropometric measures were obtained from 120
PWS subjects and standardized growth charts representing
7 percentile ranges were developed along with the norma-
tive third, 50th, and 97th percentiles from national and
international data. PSW-specific growth standards must be
used in subjects with PWS to monitor growth patterns and
nutritional status and plan individual medical care, diet
intervention and physical activities.
Regarding autoimmune endocrine disorders disease, only
few reports have found that in childhood, Graves’ disease
(GD) and Hashimoto’s thyroiditis (HT) may follow one an-
other in the same individuals. These autoimmune thyroid
disorders are more frequent in patients with Turner syn-
drome or Down syndrome. Aversa et al. [31] retrospectively
analysed the sequential phenotypic conversion from HT to
GD and the subsequent evolution of GD in a series of 12
children and adolescents with Down syndrome. All were
prepubertal except one. Patients with HT diagnosis differed
in thyroid hormone levels and in use of L-thyroxine. Time
interval between HT diagnosis and GD onset ranged from
0.7 to 6.5 years (median 4.2). There was no correlation be-
tween duration of L-thyroxine treatment and time interval
HT – GD. After metimazole withdrawal, one third of pa-
tients exhibited a spontaneous change of thyroid function,
from hyperthyroidism to hypothyroidism and needed L-
thyroxine treatment. These children did not significantly
differ from the other ones in thyroid function tests, serum
autoantibody levels at HT diagnosis or in thyrotropin re-
ceptor autoantibodies values at GD presentation. These
data indicate that children with Down syndrome might
manifest over time a phenotypic metamorphosis from HT
to GD and they may subsequently fluctuate from hyperthy-
roidism to hypothyroidism.
The association of autoimmune thyroid disease with
autoimmune type 1 diabetes mellitus is well established
[32]. Balsamo et al. [33] enrolled 152 children and adoles-
cents at type 1 diabetes mellitus onset who had positive an-
tithyroid antibody in 11 % of cases. They observed that
thyroid function at type 1 diabetes mellitus onset is im-
paired mainly in association with metabolic derangement,
irrespective of thyroid autoimmunity. Patients with antithy-
roid antibodies at type 1 diabetes mellitus onset were at
higher risk of developing hypothyroidism over time.
Gastroenterology
Several studies on celiac disease (CD) and non-celiac glu-
ten sensitivity have added insights into pathophysiology
and treatment. Sarno et al. [34] recognized that according
to family studies, 87 % of celiac disease (CD) heritability
could be explained. Among genetic factors associated with
CD, they described risk loci, including genetic human
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leukocyte antigen HLA class II region, HLA-DQ2 or
HLA-DQ8 haplotypes, major histocompatibility complex
class I region and non-HLA genes. They reviewed several
studies that evaluated the role of environmental factors
for triggering CD in the population with genetic predis-
position. They noted that neither breastfeeding nor timing
of gluten introduction reduced the risk for CD develop-
ment. They point out that CD risk might be reduced by
avoidance of high amounts of gluten in the first year of life
[35]. Finally early infections, especially due to adenovirus
and rotavirus, may have an impact on the risk of CD by
inducing inflammatory T cell responses. Future studies on
reduction of immunogenic gluten and vaccination may be
helpful to develop an effective prevention of CD. Non-
celiac gluten sensitivity [36, 37] is a recently documented
syndrome caused by ingestion of gluten whose symptoms
should be mainly distinguished from irritable bowel syn-
drome [38]. A consensus conference [39] has proposed
new criteria for identifying non-celiac gluten sensitivity
after excluding celiac disease or allergy to wheat. Non-
celiac gluten sensitivity should be suspected when there is
a decrease of >30 % from the baseline score of a standard-
ized questionnaire for at least 50 % of a 6-week strict
gluten-free diet. The definitive mean for the diagnosis is a
positive double-blind placebo-controlled challenge. The
challenge consists in a 1-week gluten diet (8 g) followed
by a 1-week gluten-free diet and then a second 1-week
challenge. Response to challenge should be assessed by
the questionnaire whose results are positive when there is
>30 % score variation between the gluten and the placebo
challenge. As recognized by Authors [39], the threshold of
30 % increment in symptoms needs to be validated.
Genetics
Sex chromosomal aneuploidies in males are rare diseases
with an overwhelming involvement of endocrinological and
auxological issues. The most common of them is Klinefelter
syndrome (KS) [40]. Brain magnetic resonance imaging
(MRI) studies on KS have provided evidence that sex-
chromosome polysomy exerts specific effects on brain de-
velopment. Milani et al. [41] described a patient with a
48,XXXY/49,XXXXY mosaicism who showed some un-
usual neuroradiological features. The patient is a 20-
months-old boy, who at birth had facial dysmorphysms,
inverted nipples, and ventricular septal defect. He was first
visited because of developmental delay, congenital heart de-
fect and hypogenitalism. An MRI showed an asymmetric
dysmorphic appearance of the posterior cranial fossa, that
had small size, with dysmorphism of cranio-cervical junc-
tion and reduced visualization of cerebrospinal fluid spaces,
that were confirmed at the computerized tomography.
Brain abnormalities are frequently found in KS variants [42,
43], but also neurocognitive abnormalities, like as auditory
and motor systems that often in KS are selectively affected
[44]. Therefore, the supernumerary X chromosome seems
to have a negative effect on white matter and central ner-
vous system development. The patient described is the first
case of a cranio-cervical junction malformation associated
with 48,XXXY/ 49,XXXXY syndrome. It is important to
underline that skeletal abnormalities are not exclusively re-
lated to the limbs, but also to the axial structures (such as
the cervical spine), thus suggesting that the neuroradiologi-
cal assessment is potentially useful in the diagnostic ap-
proach to patients with 48,XXXY and 49,XXXXY
syndrome. Rubinstein-Taybi syndrome (RSTS) is an ex-
tremely rare multiple congenital anomaly/intellectual dis-
ability syndrome, with an estimated prevalence of one case
per 125,000 live births. Given the complexity and rarity of
RSTS, there are still numerous unanswered questions about
it. In this review Milani et al. summarized the clinical fea-
tures and genetic basis of RSTS, and highlighted the areas
for future studies on appropriate diagnostic protocol and
follow-up care for RSTS [45]. RSTS is characterized by slow
development of height and weight, microcephaly, dys-
morphic facial features, broad thumbs, and big toes. Over
90 % of individuals survive to adulthood, and healthcare for
these patients is particularly complex, time-consuming, and
often not standardized in specific guidelines. The gene most
frequently involved is CREBBP [46]. Alterations in the
E1A-binding protein p300 have also been detected, but
many cases have been diagnosed only on a clinical basis
[47]. Little is known about genotype-phenotype correlations
in RSTS. Recurrent mutations maybe a key tool in address-
ing genotype-phenotype correlations in patients sharing the
same defects and specific clinical signs, as demonstrated in
two cases in a clinical cohort of 46 RSTS patients [48].
Nevertheless, a severe phenotype has been reported in
RSTS patients who show large gene deletions. Novel gen-
etic and epigenetic therapies may be promising, but there is
still an urgent need to improve and personalize the stand-
ard follow up protocol [49]. In order to improve it, the au-
thors drafted their follow-up proposal.
Haematology
Children with immune trombocytopenia and sickle-cell
anemia (SCA) have been intensively investigated. Child-
hood immune thrombocytopenia is frequently a self-
limiting disease, however in 13–36 % of cases it lasts more
than 12 months and it is classified as chronic. Current
treatments include immunosuppressors, such as corticoste-
roids and rituximab, immunoglobulins, and splenectomy,
with high side-effects and potential short-term and long-
term risks. Eltrombopag is an oral non-peptide thrombo-
poietin receptor agonist that binds to the transmembrane
domain of the thrombopoietin receptor, leading to signal
transduction through various pathways, including Jak/
STAT and MAPK, which results in proliferation and differ-
entiation of megakaryocytes and increased platelet
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production. Eltrombopag is an effective therapy for chronic
immune thrombocytopenia, severe aplastic anemia, and
chronic hepatitis C-associated thrombocytopenia in adults.
The effect of eltrombopag in children with chronic immune
thrombocytopenia have been investigated by two parallel
randomised, multicentre, placebo controlled trials, PETIT
trial [50], as a phase 2 trial, and PETIT2 study [51] as the
phase 3 trial. In PETIT study, eltrombopag produced a sus-
tained platelet response of 50x109 per L in 62 % of patients
vs 32 % in placebo group, from week 1 to week 6; in
PETIT2 study, in 40 % of children vs 3 % in placebo group,
in the double-blind period of 13 weeks. During the open-
label phase, about 80 % of patients achieved a platelet count
of 50 × 109 per L or more at least once in both studies. Re-
duction in bleeding was also observed. Adverse events were
mostly mild and serious adverse events (reversible in-
creased alanine aminotransferase concentrations, pneumo-
nia, aseptic meningitis, neutropenia, and anemia) were
infrequent. At variance from adults, no malignancy and
thrombosis occurred. Further data on cost, availability of
more effective options, assessment of patient-reported out-
comes and patient adherence to long-term daily medication
are warranted to understand whether eltrombopag is a suit-
able therapeutic option for children with chronic immune
thrombocytopenia in clinical practice [52].
Children with SCA are prone to sleep pathology be-
cause of smaller bladder capacity during sleep, hypos-
tenuria, increased arousal thresholds, sleep-disordered
breathing (obstructive sleep apnea syndrome). Mascar-
enhas et al. [53] performed a retrospective study com-
paring polysomnography results in 65 children with
SCA versus 65 children without SCA with suspected
OSAS. Mean SpO2 and minimum SpO2 were signifi-
cantly lower in SCA patients. No significant difference
was found between groups in efficiency, latency and
percentage of sleep phases. SCA group was at higher
risk for nocturnal enuresis (35.4 % vs 6.2 %, p < 0.01).
Eneh et al. [54] performed a questionnaire-based,
case–control study evaluating nocturnal enuresis and
possible risk factors among 70 children, aged 5 to
11 years, with SCA and 70 age- and sex-matched
controls. Although, there was no difference in noctur-
nal enuresis between the 2 groups, the prevalence of
nocturnal enuresis was significantly higher in males
with SCA than in male controls and in subjects
whose parents had a childhood history of enuresis.
They found no relationship with socio-economic sta-
tus. Their findings show that reduced responsiveness
to toilet training in boys and familiar predisposition
may play a role in nocturnal enuresis. This study
point out that school children with SCA should be
frequently evaluated for nocturnal enuresis, particu-
larly if they are males and have parental history of
nocturnal enuresis in childhood.
Infectious diseases
Epidemiologic studies continue to document changes
in the post-vaccination era. In the United States Mac-
Neil et al. [55] found that Neisseria meningitidis re-
mains an important cause of infectious disease in
children <1 year, despite the use of pneumococcal
vaccines in infants. They collected data from active,
population- and laboratory-based surveillance, includ-
ing cultures from blood, CSF, joint or pleural fluid for
N. meningitidis, during 2006 through 2012. They esti-
mated 113 cases annually of meningococcal disease
among infants aged <1 year, for an overall incidence
of 2.74 per 100 000 infants and a death rate of 6
children per year. Serogroup B was responsible for
64 % of cases, followed by serogroup Y and C respon-
sible for 16 and 12 % of infant cases respectively. Au-
thors suggest that future meningococcal disease
vaccination strategies should be targeted on serogroup
B meningococcal disease. Furthermore, they may in-
clude a maternal vaccination program to protect in-
fants aged <1 year as they would be too young to
have received the minimum 2 or 3 doses of vaccine
that are needed to prevent the disease.
Azzari et al. [56] studied the burden of bacteremia and
invasive disease (ID) in 920 children less than 5 years
old with a fever of 39 °C or greater in a prospective,
multi-centre, hospital-based study. They found ID in
225 children, sepsis in 38 and non-invasive disease in
629. Twenty-two (9.8) children with ID, 2 (5.3) with sep-
sis and 10 (1.6 %) with a clinical diagnosis of non-
invasive disease were bacteremic, having at least one
positive sample, detected either by molecular assessment
(PCR), culture, or both. In children with bacteremia, the
most common diagnoses were community-acquired
pneumonia (15/34), pleural effusion (4/34) and meningi-
tis (4/34). It was noted a higher sensitivity of molecular
versus cultural techniques for detecting bacteremia.
Among bacteremic cases, Streptococcus pneumoniae was
detected in 85.3 % (29/34) of cases, Haemophilus influ-
enzae in 3 (2 non-typeable and 1 capsulated), Escheri-
chia Coli in 1, and Neisseria meningitidis in 1. The most
commonly detected Streptococcus pneumoniae serotype
was 19A, detected in four cases. Community-acquired
pneumonia was due to Streptococcus pneumoniae in 14
children, 3 due to serotype 3 and 3 due to serotype 14.
Pleural effusion were always due to Streptococcus pneu-
moniae, meningitis were due to Streptococcus pneumo-
niae in 3 patients and to Neisseria meningitides in 1.
The mean direct medical cost of bacteremic cases was
3306 euro. This study confirms that Streptococcus pyo-
genes is an important global pathogen, causing consider-
able morbidity in the paediatric population with high
costs and it indicates the need for preventing pneumo-
coccal infection by vaccination.
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In the past, the belief that measles, mumps and rubella
vaccination may cause autism had induced some parents
to not immunize their children. Using an administrative
claims database associated with a large US health plan,
Jain et al. [57] confirmed that measles, mumps and rubella
vaccine was not associated with an increased risk of autis-
tic spectrum disorder at any age in 95 727 children. They
found that children with an older sibling with autistic
spectrum disorder, more frequently develop autistic
spectrum disorder, compared with those with siblings
without autistic spectrum disorder (p < .001). It is reassur-
ing that families with a child already affected by autism
were not less likely to have younger children vaccinated.
Numerous studies are evaluating measures to prevent
the risk of infectious diseases. In low-income countries,
Rotavirus disease occurs at a younger age than in high-
income countries and in regions with a high burden of
Rotavirus disease the success of Rotavirus vaccine is often
suboptimal. Bines et al. [58] showed that coverage and ef-
ficacy of oral RV3-BB rotavirus vaccine derived from new-
born with asymptomatic rotavirus infection are improved
by a dose of rotavirus vaccine given at birth. In a phase 2a
randomized, double-blind, three-arm, placebo-controlled
trial, participants were randomized to oral RV3-BB rota-
virus vaccine with the first dose given at 0–5 days after
birth (neonatal schedule, 30 participants), to vaccine with
the first dose given at about 8 weeks of age (infant sched-
ule, 27 participants), or to placebo (32 participants). After
randomization children received four oral doses of prod-
uct at around 8 week intervals. The primary outcome was
cumulative vaccine take (a serum immune response of
anti-rotavirus IgA or serum neutralizing antibodies or de-
tection of RV3-BB virus in stool after administration of
vaccine or placebo) after three doses of RV3-BB. The
RV3-BB rotavirus vaccine was found to be immunogenic
with a positive cumulative vaccine take detected in 90 and
93 % of participants after three doses in a neonatal or an
infant schedule, respectively, and well tolerated. Acute oti-
tis media (AOM) in children can be managed without an-
tibiotics. However, it is the most common reason for their
use. Overusing antibiotic may increase serious side effects,
antibiotic resistance and costs. Streptococcus salivarius
24SMB is able to produce bacteriocin-like substances with
significant activity against AOM pathogens [59]. Marchi-
sio et al. [60] investigated the efficacy of Streptococcus sali-
varius 24SMB nasal spray in preventing AOM in 100
otitis-prone children, aged 1–5 years, with recurrent
AOM in a randomized, double-blind, placebo controlled
trial. Children received intranasal S. salivarius 24SMB or
placebo twice daily for 5 days each month for 3 consecu-
tive months. When enrolled, the children were free of
AOM. They were initially treated with amoxicillin-
clavulanic acid for 10 days, to facilitate S. salivarius
24SMB colonization. During the study, when an AOM
were diagnosed it was treated with amoxicillin plus clavu-
lanic acid for 10 days. In the group treated with S. salivar-
ius 24SMB, fewer children experienced any AOM in
comparison with those in the placebo group (30.0 vs
14.9 %; p = 0.076). The number of children colonized by S.
salivarius 24SMB who experienced any AOM was signifi-
cantly lower compared with the children who were not
colonized. The nasal administration of S. salivarius
24SMB was safe and well tolerated. In clinical practice,
limitations of the study [61] include use of amoxicillin-
clavulanic acid as first line antibiotic in AOM instead of
amoxicillin and treatment of all enrolled children with an
amoxicillin-clavulanic acid even if they were healthy at
baseline. This can lead to an increasing antibiotic resist-
ance and it is in contrast with a 2010 Italian pediatric
guideline for the treatment of AOM [62] that recom-
mended a “watchful waiting” approach for children with
AOM to decrease the use of antibiotic. Unfortunately,
watchful waiting strategy is still far from routine use and
the antibiotic prescription rate continues to be high.
Palma et al. [63] found no difference in the frequency of
antibiotic prescriptions between before the publication of
the guideline and after, both in a whole population of
4,573 children with AOM seen at the Pediatric Emergency
Department (82 % versus 81 %) and in all age classes. The
most frequently prescribed antibiotic was amoxicillin-
clavulanic acid (51 %) and its prescription rate was similar
before and after guideline publication.
Neonatology
Infants admitted to neonatal intensive care units (NICU),
especially extremely low birth weight infants often receive
an empirical antibiotic treatment, even if proven sepsis is
diagnosed in a minority of cases [64]. Tzialla et al. [65]
underline that unnecessary empirical administration of
broad-spectrum antibiotics should be limited since it is as-
sociated with increasing multi-drug resistant bacterial in-
fections, alteration of gut colonization which may lead to
necrotizing enterocolitis (NEC) and increasing risk of in-
vasive candidiasis. They also summarize current know-
ledge on the appropriate choice of antimicrobial agents
and optimal duration of therapy in newborns with sus-
pected or culture-proven sepsis. In the absence of ran-
domized controlled trials that can definitely prove the best
choice of antibiotics, an association of a penicillin or semi-
synthetic penicillin together with an aminoglycoside can
be considered the best empirical regimen for early-onset
sepsis [66]. Antistaphylococcal penicillin (oxacillin, flu-
cloxacillin) plus an aminoglycoside should be the best op-
tion for late-onset sepsis (LOS); vancomycin should be
given when infection by methicillin-resistant Staphylococ-
cus aureus or coagulase-negative Staphylococcus is proven.
Diagnosis of late-onset neonatal sepsis (LOS) can be diffi-
cult because clinical manifestations are not specific and
Caffarelli et al. Italian Journal of Pediatrics  (2016) 42:75 Page 7 of 17
none of the available laboratory tests can be considered an
ideal marker. Poggi et al. [67] showed that presepsin
(sCD14-ST) (P-SEP) may be an accurate marker for iden-
tifying LOS in preterm newborns. Presepsin is a soluble
N-terminal fragment of the cluster of differentiation
marker protein CD14, which is released into the circula-
tion during monocyte activation upon the recognition of
lipopolysaccharide from infectious agents. A prospective
single-centre study on newborns <32 weeks’ gestational
age who developed possible LOS was conducted. Blood
samples for culture and count and for measuring P-SEP,
procalcitonin, CRP were taken at enrolment (T0) and 1
(T1), 3 (T3), and 5 (T5) days after the first sample. P -SEP
values were significantly higher in the LOS group (n = 21)
than in the control group (n = 19) at any time. P-SEP
achieved the best accuracy for prediction of probable sep-
sis at the cut-off of 885 ng/L with 94 sensitivity (95 CI 74–
100) and 100 % specificity (95 % CI 84–100). Larger stud-
ies are required to confirm the role of P-SEP in early diag-
nosis of sepsis.
NEC is a multifactorial disease associated with prema-
turity. Use of broad-spectrum antimicrobials and dysbiosis
[68, 69], may play a role in NEC onset. Therefore, interest
is growing in preventing NEC by given oral probiotics
[70]. Along this line, in a meta-analysis Aceti et al. [71] se-
lected twenty-six studies on the effect of probiotics for
preventing NEC in preterm infants. The majority of stud-
ies had severe or moderate flaws. However, they found
that probiotics may be effective in preterm and in very-
low-birth-weight infants. Data were still insufficient in
extremely-low-birth weight infants. A significant effect
was found for Bifidobacteria and for probiotic mixtures.
Well-designed studies are warranted to clarify the choice
of the most effective strain, dose and duration of supple-
mentation before recommending use of probiotics in clin-
ical routine [70]. Other comorbidities of prematurity, such
as delayed enteral feeding, low availability of human milk
[72] and immunodeficiency [73] may favour NEC occur-
rence. Christensen et al. [74] found that neutropenic neo-
nates have a significant higher risk for developing NEC.
Neutropenia increased with prematurity and it was more
common among small for gestational age neonates. Neo-
nates with neutropenia were treated with either recombin-
ant granulocyte colony-stimulating factor or intravenous
immunoglobulin, but unfortunately, there was no reduc-
tion in LOS or NEC [74].
Respiratory distress syndrome at birth is one of the most
frequent causes of admission to the NICU. More fre-
quently due to pulmonary disease, and rarely to an extra
pulmonary cause, such as a mediastinal mass. The first
case of thymic haemorrhage was described by Ribet et al.
in 1971 [75]. Gargano et al. [76] described a case of thymic
haemorrhage with perinatal onset, associated with bilat-
eral haemothorax and severe respiratory distress at birth.
Thymic enlargement was evident after pleural evacuation
and confirmed by chest conventional radiography, com-
puted tomography (CT) and MRI sequences. The spon-
taneous resolution of the enlarged thymus suggested a
thymic haemorrhage that did not require surgery. Thymic
haemorrhage in the perinatal period is an exceedingly rare
and severe condition that often leads to stillbirth or severe
respiratory distress at birth. Spontaneous thymic haemor-
rhage should be considered in any neonate developing
acute respiratory distress with widening of the mediasti-
num and pleural effusion on chest radiography.
Neonatal hyperbilirubinemia is commonly due to an
increase in unconjugated bilirubin that is usually benign
and it resolves spontaneously. On the contrary, conju-
gated hyperbilirubinemia is infrequent and it should be
promptly investigated. An evidence-based guideline for
the management of new-borns with cholestasis [77] has
been delivered this year. Early recognition of cholestasis
helps to optimize the clinical management, to prevent
clinical deterioration, to avoid premature, painful, expen-
sive, and useless tests and to reduce underestimation
and late referral. Many conditions can cause neonatal
cholestasis and require medical or surgical treatment.
The largest diagnostic group of patients includes those
with biliary atresia. The clinical presentation of neonatal
cholestasis may vary in relation to its aetiology. Never-
theless, the most common findings in an infant with
cholestasis are prolonged jaundice, defined as jaundice
lasting more than 14 days or recurring after the second
week of life, acholic stools, dark yellow urine, and hep-
atomegaly. A practical approach for the management of
the neonatal cholestasis in term and preterm infants has
been provided [77]. Goetze et al. [78] recommended ini-
tial treatment and a clinically oriented overview of pos-
sible differential diagnoses.
Massage therapy is a safe practice that can promote
interaction between the mother and the infant, can im-
prove weight gain, sleep patterns, growth, development,
and autonomic nervous system functions, and can re-
duce rates of colic and infant mortality. Some clinical
studies support the use of massage for reducing neonatal
jaundice [79, 80], otherwise the apparent correlation has
not yet been extensively examined among neonates with
jaundice who are receiving phototherapy. Lin et al. [81]
investigated the effects of infant massage on newborns
with jaundice who are also receiving phototherapy. A
total of 56 full-term neonates with jaundice, admitted
for phototherapy at a regional teaching hospital, were in-
cluded in the final study and randomly assigned to the
control group (29 neonates; 16 males and 13 females)
and the massage group (27 neonates; 11 males and 16
females). Authors showed that by day 3 of intervention,
bilirubin levels were significantly lower in the massage
group while stool frequency was significantly higher.
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Iron is an essential nutrient and plays a key role in
many processes including human growth and develop-
ment [82]. Low birth weight infants are particularly sus-
ceptible to develop iron deficiency anemia since they
typically have small iron stores at birth and a greater
need for iron due to the rapid increase in red cell mass
[83, 84]. Nevertheless, it is currently unclear at what
time iron supplementation in preterm very low birth
weight infants should start. The report of Hong-Xing Jin
et al. provides further insight into the issue of the timing
of iron administration by evaluating early versus late
iron supplementation in low birth weight infants
through a meta-analysis of currently published studies
[85]. Early supplementation ranged from as early as en-
teral feeding was tolerated to 3 weeks, and late supple-
mentation ranged from 4 weeks to about 60 days. Early
treatment was associated with significant smaller de-
crease in serum ferritin and haemoglobin levels (p <
0.001). In addition, the rate of blood transfusions was
lower in early compared to late iron supplemented pa-
tients (p = 0.022). There was no difference between early
and late supplementation in the number of patients who
experienced NEC. Despite these results, authors recom-
mended much caution when low birth weight infants are
supplemented with iron as iron overload may have nega-
tive long-term effects on the neurodevelopment [86].
Neonates born with meconium stained amniotic fluid
(MSAF) can develop feed intolerance in the first post-
natal period of life. Gastric lavage is performed routinely
in neonates with MSAF, but it is not a safe procedure as
several complications have been described. The aim of
Shah et al. [87] was to investigate the role of gastric lav-
age in vigorous late preterm and term newborns born
with MSAF in a non-blinded randomized controlled trial
conducted. No significant difference in the incidence of
vomiting was found between 230 cases who received the
gastric lavage, and 270 who did not. Feed intolerance
was described in 51 neonates, with no significant differ-
ence in relation to the gestational age, gender, birth
weight and modes of delivery. No complications of naso-
gastric tube insertion such as apnoea, bradycardia and
local tissue trauma were observed in the gastric lavage
group. These findings suggest that gastric lavage is not
required in vigorous neonates born through MSAF to
avoid feeding intolerance. Nevertheless, this topic is still
debated. A systematic review of randomised controlled
trials showed controversial evidences [88]. No associ-
ation of feeding intolerance with gender or birth weight
and gestation was found [89].
Nephrology
Relapses and complications of nephrotic syndrome (NS),
the most common manifestation of glomerular disease in
childhood have been an active area of investigation. In
children with steroid-sensitive nephrotic syndrome, re-
lapses occur in most instances and 20 % to 60 % of pa-
tients develop steroid dependence. Uwaezuoke [90]
reviewed triggers of relapses and their possible treatments.
They documented that relapses may occur after viral in-
fections, such as viral upper respiratory tract infections,
urinary tract infections, diarrhea, or an atopic episode.
This would support the hypothesis that relapses are
caused by an ‘immune dysregulation’ and it is in agree-
ment with findings of abnormalities of T cell subsets and/
or T function. Rituximab a chimeric monoclonal antibody
against CD 20 receptors on B cells may reduce proteinuria
by inducing regulatory T cells. They also noted that re-
lapses might be provoked by a systemic circulating factor
or a primary defect of podocytes which might result in in-
creased glomerular permeability. Corticosteroids and cal-
cineurin inhibitors influence structure and function of
podocytes. Finally, they reported that effective strategies
for relapses in NS have been developed. In children, the
risk for relapse has been shown to be reduced by giving
prednisolone during upper respiratory infection. Zinc sup-
plements prevent respiratory infections and reduce relapse
rates in children. Ishikura et al. [91] in a long term follow-
up study of 46 Japanese children with frequently relapsing
NS, after an initial 2-year treatment of cyclosporine (CsA),
showed that half of the patients still continued to relapse
frequently or were on immunosuppressive agents at the
last observation (mean age 18.7 years). They postulated
that there may be an association between the experience
of NS relapse during cyclosporine treatment and poorer
outcome at the last observation. Fujinaga and Hirano [92]
recruited 52 children with NS (median age 12.2 years). All
patients had steroid-dependent NS (SDNS) or steroid-
resistant NS (SRNS) and they were prescribed CsA for a
median period of 39.5 months before being started on my-
cophenolate mofetil (MMF). During the follow-up period
(median 6.1 years) after starting treatment with MMF,
only 3 patients did not experience a relapse of NS, 14 were
re-treated with CsA and 27 received rituximab infusions.
At the last visit (median age 18.3 years), 19 patients (37 %)
did not require any immunosuppressive agent, while 33
(63 %) continued to receive immunosuppressive agents.
Univariate analysis revealed that the risk of persistent
SDNS after MMF treatment, was positively associated
with occurrence of SDNS during CsA treatment (24/33
vs. 3/19; p = 0.00019) and administration of rituximab dur-
ing CsA treatment (12/33 vs. 0/19; p = 0.0017). Onset of
relapse during initial CsA treatment predicts the poor
clinical course of NS in the long run. The introduction of
MMF following CsA treatment may not positively influ-
ence the long-term outcome in patients with SRNS and
SDNS. McCaffrey et al. [93] reviewed the available evi-
dence on complications of idiopathic NS and provided a
guide for appropriate treatment. Infections should be
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treated promptly with broad-spectrum antibiotics in the
nephrotic child. The role of antibiotic prophylaxis is still
unclear, and data on the efficacy of the pneumococcal vac-
cine are lacking. Thromboembolic disease in NS may have
potentially devastating effects, but whether primary
prophylaxis is warranted is unknown. NS population are
at risk for long-term cardiovascular disease and dyslipid-
emia, so novel management strategies, such as modifying
sialylation of the circulating glycoprotein angiopoietin-like
4, have shown promising results.
Neurology
New insights into the pathophysiology of cerebral palsy,
arterial ischemic stroke and acute encephalitis may drive
advances in treatment. Cerebral palsy affects about 2 of
every 1000 children. Preventing strategies are needed be-
cause of lack of effective treatments. Nelson et al. [94]
analysed which factors operating before labor may in-
crease the risk of cerebral palsy. Such factors include birth
defects, defined as structural or functional defects present
at birth, even if they are not recognized in the newborn
period. Brain defects and congenital cardiac defects are
common in children born at a gestational age of at least
35 weeks with cerebral palsy. Cerebral palsy is more likely
when birth defects and fetal growth restriction are com-
bined [95]. Cerebral palsy is also associated with low ges-
tational age at birth, probably due to disorders that lead to
malformation and delivery before term. On the other
hand, malformations are more likely in at term infants
with cerebral palsy. Other important risk factors for cere-
bral palsy are marked foetal restricted growth, especially
in subjects with major birth defects, intrauterine infections
(cytomegalovirus), and thromboembolism in brain, other
organs and placenta. Thromboembolism may lead to mal-
formations and perinatal stroke, the most common cause
of cerebral palsy in children born at term. Finally, it has
been found that a genetic component [96] is involved in
many cases of cerebral palsy, especially when an older sib-
ling is affected. A prevention programme should be based
on early investigation of key prenatal risk factors for cere-
bral palsy, including birth defects, fetal growth restriction,
and neonatal encephalopathy, that may act directly or may
co-operate with other exposures or intrapartum events
such asphyxia.
In childhood, stroke is rare but the incidence of arterial
ischemic stroke (AIS) in the neonate is similar to the inci-
dence of large artery AIS in adults and is 17 times greater
than the incidence of AIS in children. AIS is associated with
a significant morbidity and mortality. In term neonates,
AIS is the most common cause of cerebral palsy and is the
second most common of seizures. Therefore, challenges
presented by children with stroke have been the subject of
considerable interest. Mechanisms, diagnosis and manage-
ment of AIS in children have been summarized by Rosa
et al. [97]. They documented that factors associated with
AIS in childhood differ from those in adults. Focal cerebral
arteriopathy caused by infections or genetically determined
(Moyamoya Syndrome) seems to be the main cause. Other
factors involved in the occurrence of AIS are vasculitis, ar-
teriovenous malformation or dysplasia, hereditary coagu-
lopathies, hematologic disorders, SCA, infarctions due to
metabolic diseases, head or neck trauma, congenital and
acquired heart disease. They pointed out that clinical pres-
entation of stroke depends on the involved artery and pa-
tient’s age. Seizures and headache may develop irrespective
of stroke subtype. Infants with stroke often present aspeci-
fic manifestations. Seizures and altered mental status may
be the only symptoms. They emphasized that the corner-
stone for diagnosing paediatric stroke is neuroimaging. In
emergency settings, the diagnostic importance of non-
contrast Computer Tomography has been underlined.
However, MRI remains the “gold standard”. MRI Angiog-
raphy should be useful to assess the involved territory. Vas-
cular imaging of the carotid and vertebral arteries by
duplex ultrasonography, Computer Tomography angiog-
raphy, and catheter angiography should be considered. La-
boratory tests for the investigation of diseases associated
with AIS in infants and children should be performed.
Understanding of the underlying etiology of AIS pro-
vides a basis for choosing the best therapeutic options.
After excluding a haemorrhagic stroke, anticoagulant
therapy is mandatory using aspirin or heparin. Thromb-
olysis may be considered. Further episodes of AIS may
be prevented by Acetil-salycilic acid. Low molecular-
weight heparin or warfarin are useful in children with
cardioembolism, extracranial arterial dissection, cerebral
venous sinus thrombosis and when aspirin treatment
fails. Rosa et al. acknowledge that further studies are
warranted to optimize antithrombotic treatment. Con-
trol of associated diseases, such as SCA or metabolic
diseases is also recommended for secondary stroke pre-
vention. Finally, rehabilitation can reduce long-term
morbidity and improve quality of life.
Encephalitis is a serious and disabling condition that
can result from a large number of causes even if many
cases remain undiagnosed. In a case series of acute en-
cephalitis, Pillai et al. [98] provides insights into the rela-
tive frequency of causes. They observed that 49 (30 %)
of 164 children had an infectious encephalitis, 13 (8 %)
children had an infection associate encephalopathy.
Pathogens detected in infectious encephalitis were
enterovirus (12), mycoplasma pneumoniae (7), herpes
simplex virus (5), and cytomegalovirus 2 %, in infection-
associated encephalopathy, influenza virus and rotavirus.
Immune-mediated/autoantibody-associated encephalitis
was diagnosed in 56 (34 %) children. It was due to acute
disseminated encephalomyelitis in 21 % of cases, N-
methyl-D-aspartate receptor antibody encephalitis in
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6 % of cases, voltage-gated potassium channel complex
antibody encephalitis in 4 % of cases. In 46 (28 %) pa-
tients, the cause of encephalitis was unknown. Young
children were more frequently affected with a median
age at presentation of 5.5 years. The peak was during
the winter season. Risk factors for poor outcomes were
intensive care unit admission, diffuse restriction on MRI
and status epilepticus.
Nutrition
This year saw the publication of the position statement of
the Task Force on Breastfeeding of the Ministry of Health,
the Italian Society of Neonatology, the Italian Society of
Primary Pediatric Care and the Italian Society of Pediatric
Gastroenterology and Nutrition [99]. They pointed out
that breastfeeding is of benefit to the mother and the in-
fant and should be promoted not only by neonatologists
and pediatricians, but also by professionals, especially in
maternity hospitals. They recommended exclusive breast-
feeding for about 6 months of life. They emphasized that
poor growth may suggest anticipating the introduction of
weaning foods after 4 months of age. In agreement with
those recommendation, there is evidence that starting
breastfeeding within the first hour of life was associated
with a reduced risk of neonatal mortality [100]. Moreover,
exclusively breastfed newborns had a lower risk of mortal-
ity and infection-related deaths in the first month than
partially breastfed neonates. Exclusively breastfed new-
borns also had a significant lower risk of sepsis, diarrhea
and respiratory infections compared with those partially
breastfed [100]. Khan et al. [100] concluded that substan-
tial benefits in reducing neonatal mortality and morbidity
can be achieved with effective promotion of early initi-
ation of breastfeeding and exclusive breastfeeding during
the first month of life.
Giugliani et al. [101] reviewed studies that evaluated
the effect of any type of intervention for promoting
breastfeeding on child weight, length (or height) and
weight/height (or BMI). Meta-analyses of studies report-
ing on mean weight, length, weight/length or BMI
showed that the interventions had no impact on weight
or length/height z scores and had a modest, but signifi-
cant, reduction in body mass index/weight-for-height z
scores, which was limited to studies from low- and high-
incomes settings. An important heterogeneity among
studies should be taken into account when interpreting
the results. Authors stated that it is not possible to have
a conclusive analysis of the impact of breastfeeding pro-
motion interventions on child growth, although these
seem to have little influence on child growth. Neverthe-
less, breastfeeding promotion must remain a priority, as
many other benefits to the child and mother are already
well established.
Breast milk provides both protective and stimulatory
immune signals, which may confer lower susceptibility to
disorders such as allergic disease. Lodge et al. [102] sys-
tematically review the association between breastfeeding
and childhood allergic disease. Longer duration of breast-
feeding was associated with reduced risk of asthma for
children (5–18 years), particularly in medium-/low-in-
come countries, but this estimate had high heterogeneity
and low quality. Exclusive breastfeeding for 3–4 months
was associated with reduced risk of eczema ≤2 years (esti-
mate principally from cross-sectional studies of low meth-
odological quality). No association was found between
breastfeeding and food allergy (estimate had high hetero-
geneity and low quality).
The recommendations concerning complementary feed-
ing from the Italian Society of Gastroenterology,
Hepathology and Pediatric Nutrition and the Italian Soci-
ety of Pediatric Allergy and Immunology Emilia Romagna
[103] have been issued. Solid foods should be introduced
between 4 and 6 months of age when the 6 months limit
is not possible. An early exposure (before 4 months of
age) or a delayed introduction of the main allergenic foods
(after 6 months of age) has not been found to be useful to
prevent allergy, even if infants were at risk of atopy. They
noted that weaning while continuing breastfeeding might
reduce the onset of allergies. The timing of introduction
and amount of gluten has no effect on the onset of coeliac
disease. The timing of introduction of complementary
feeding is not related with the risk of obesity, T2DM and
cardiovascular disease in later ages. They emphasized that
infants should go on a nutritionally balanced diet, encour-
aging the daily consumption of fruit and vegetables. They
recommended providing parents with the right informa-
tion about daily intake of carbohydrates, lipids, proteins,
liquids, fibers, vitamins and minerals. Baby led weaning
and auto-weaning were discussed as a promising way for
introducing complementary foods which respects the
child’s self-regulatory capacity. They point out that baby
led weaning is feasible when infants achieve postural sta-
bility to sit and to grasp objects.
Zheng et al. [104] emphasized the risk of early wean-
ing. They investigated the association between timing
and types of complementary feeding and adiposity in
children of 4–5 years of age enrolled in the Jiaxing birth
cohort. Among 40510 children, 3.18 were overweight
and 64.8 % were fed complementary food before
3 months of age. Early introduction of complementary
foods before 3 months of age, was associated with
greater BMI z-score (P-trend < .001) and higher risk of
overweight (P-trend = .033). No significant association
between timing of complementary feeding and obesity
was observed. Fish liver oil was the major type of com-
plementary food associated with adiposity when it was
introduced before 3 months of age.
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Nutrition in early life is increasingly considered to be an
important factor influencing later health. There is evi-
dence that foods rich in n-3 polyunsaturated fatty acids
have protective effects on oxidative damage and inflam-
mation of the lung tissue, as in childhood wheezing and
asthma. Lumia et al. [105] explored in a birth cohort study
the association of food consumption in early life and the
risk of atopic and non-atopic asthma. Among 182 children
with asthma and 728 controls, a higher consumption of
cow’s milk products was inversely associated with the risk
of atopic asthma and higher consumption of breast milk
and oats inversely with the risk of non-atopic asthma.
Early consumption of fish was associated with a decreased
risk of all asthma. This study indicated that dietary intake
in early life combined with atopy history has an impact on
the risk of developing asthma.
A diet rich in fruits and vegetables supports healthy
weight and weight loss in the context of a reduced-caloric
diet. Moreover, it protects against chronic disease such as
diabetes, stroke, cancer, and all-cause mortality. Herrick
et al. [106] described youth fruit consumption, using data
from 3129 participants, aged 2 to 19 years, in the US Na-
tional Health and Nutrition Examination Survey. They
found that 53 of total fruit intake was consumed as whole
fruits and 34 % as fruit juices. Apples, apple juice, citrus
juice, and bananas were responsible for almost half of total
fruit consumption. There were differences by race and
Hispanic origin in intake of citrus fruits, berries, melons,
dried fruit, and citrus juices and other fruit juices. Chil-
dren aged 6 to 11 years, consumed more apples and less
bananas and other fruit juices compared with youth aged
2 to 5 years. Variations in the type of fruits consumed may
be related to taste preference, repeated exposures to fruits,
social experiences, and availability.
Augusto et al. [107] underlined the importance of effect-
ive actions to promote the consumption of fruits and vege-
tables. They studied the relationship between frequency of
fruit and vegetable consumption and nutritional deficien-
cies in 702 Brazilian schoolchildren (aged 4–10 years) in a
cross-sectional population-based study. Only 5 % of chil-
dren consumed fruits and vegetables ≥5 times/day. Overall,
6.3 of children were anaemic, 3.3 were stunted, 2.7 were
obese and 33 % had multiple nutritional deficiencies. Con-
sumption of vegetables ≤3 times/month and of fruits ≤3
times/week was associated with lower plasma concentra-
tions of carotenoids and vitamin E. Nutritional deficiencies,
including anemia, vitamin E insufficiency, vitamin D
insufficiency and stunting, were more common in non-
consumers of fruits and vegetables than in usual consumers
(vegetables ≥1 time/week and fruits ≥4 times/week).
Trends in childhood morbidity and mortality are
strongly correlated with childhood infections and under-
nutrition. Most of the morbidity and mortality from
diarrhea and pneumonia occur in children under 2 years
of age, linking it closely to early nutrition and growth.
Because of the complex interrelation between infections
and nutrition conditions, Salam et al. [108] addressed
several strategies to reduce major childhood infections
and improve nutrition and growth and implications.
These interventions include the following: exclusive
breastfeeding up to 6 months of age, promotion of
complementary feeding, pneumococcal, rotavirus and
Haemophilus influenzae type b vaccine, community-
based management of neonatal infections, case manage-
ment of pneumonia infections, use of oral rehydration
salt and zinc in diarrhea, vitamin A supplementation,
antibiotics for dysentery, and Water Sanitation and Hy-
giene strategies. Utilization of preventive interventions
will make an impact by reducing malnutrition and
under-5 morbidity and mortality.
White et al. [109] measured the prevalence of malnu-
trition, obesity and nutritional risk in 832 pediatric inpa-
tients among multiple hospitals throughout Australia in
a single day. The prevalence rates of malnourished,
wasted, stunted, overweight and obese pediatric patients
were 15, 13.8, 11.9, 8.8 and 9.9 %, respectively. Aborigi-
nal and Torres Strait Islander patients were more likely
to have lower height-for-age z-scores (P <0.01). How-
ever, BMI and weight-for-age z-scores were not signifi-
cantly different. Children who were younger, from
regional hospitals or with a primary diagnosis of cardiac
disease or cystic fibrosis had significantly lower an-
thropometric z-scores (P = 0.05). Forty-four % of patients
were identified as at high nutritional risk and requiring
further nutritional assessment. They concluded that mal-
nutrition and nutritional risk of Australian pediatric in-
patients on a given day was much higher when
compared with the healthy population. In contrast, the
proportion of overweight and obese patients was less.
Oncology
Survival after childhood cancer is greatly enhanced in
last decades. PanCare, an interdisciplinary Network of
experts in the field, has been created to identify best
practices of long-term care and address challenges in
survivors, especially related to late effects of treatment
[110]. Rhabdomyosarcoma (RMS), the most frequent
soft tissue sarcoma in childhood, can be distinguished in
embryonal RMS which occurs in 75 % of cases, with a
higher incidence at age of 0–4 years and alveolar RMS
found at every age with a worse prognosis. RMS has also
been classified basing on molecular prognostic markers.
PAX–FOXO1 fusion gene status was identified and
compared to alveolar histology, whereas fusion gene–
negative alveolar RMS patients were clinically similar to
ERMS patients. Attempts to identify other prognostic
gene signatures an independent 5-gene signature, MG5,
showed a significant association with overall survival in
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the fusion gene–negative alveolar RMS and embryonal
RMS patients. Hingorani et al. [111] studied whether ex-
pression of the MG5 metagene, measured using a tech-
nical platform that can be applied to routine pathology
material, would correlate with outcome in a cohort of
children with fusion gene–negative alveolar RMS. MG5
signature score showed a significant correlation with
overall and failure-free survival. The ability of MG5 sig-
nature was confirmed to identify different risk groups
within fusion gene–negative alveolar RMS from a differ-
ent patient cohort composed of those with intermediate-
risk disease. Ma et al. [112] explored the treatment re-
sults of childhood RMS and identified prognostic factors
in a multicenter Chinese retrospective study. Medical re-
cords of 161 patients (median age 51 months) were ana-
lyzed. The genitourinary system was the most common
primary site of tumor (43.5 %). The histological findings
were: 80.7 embryonal, 11.9 alveolar and 3.1 % botryoid
type. The 10-year event free survival rate was 53.4 ±
5.1 %, overall survival was 65.3 ± 6.3 %. Among variables,
age (p = 0.028) and disease groups (p = 0.000) were sig-
nificantly associated with overall survival. In conclusion,
epidemiological characteristics of patients of this study
were similar to worldwide data.
Sangkhathat et al. [113] described current management
of pediatric soft tissue sarcomas, based on multidisciplin-
ary approach including surgery, chemotherapy and radi-
ation therapy. Decision making in management protocol
for each patient is determined on the risk induced by vari-
ous clinical and pathological parameters. For cases of
small resectable tumors in a favorable site, surgery pro-
vides the best choice of local control. Radiation therapy is
added when surgery leaves residual disease or there is evi-
dence of regional spread. Chemotherapy reduces risks of
relapse and improves overall survival. The standard ther-
apy for pediatric RMS is a multi-agent chemotherapy and
surgery resection. This line aims to reduce the aggressive-
ness of the required surgery and frequently helps preserve
organ function. Radiotherapy is often added. Proton beam
therapy (PBT) is a type of radiotherapy with excellent dose
localization. Takizawa et al. [114] showed that PBT can be
useful in cases who cannot receive definitive photon
radiotherapy. They performed, safely and effectively, fPBT
in a 1-year-old girl with alveolar RMS with liver and car-
diac invasion at the dose of 41.4 GyE. In this case, chemo-
therapy alone was not effective; surgery was not possible
for broad tumour invasion of the surrounding diaphragm;
photon radiotherapy could not be performed because the
liver could not tolerate the treatment dose. In a retro-
spective study, Fukushima et al. [115] analyzed five chil-
dren with genitourinary/pelvic rhabdomyosarcoma (GU/
P-RMS) who had undergone multimodal therapy com-
bined with PBT in a Japanese institution. All received neo-
adjuvant chemotherapy and 3 underwent chemotherapy
during PBT (Group Cx). All patients of Group Cx devel-
oped leukocytopenia but survived by their last hospital
visit (after 36 months). They concluded that PBT was well
tolerated and could be a plausible choice instead of pho-
ton therapy for GU/P-RMS children.
Pulmonology
Deletions of or mutations in genes encoding proteins im-
portant in surfactant production and function (SP-B, SP-
C, and ABCA3), surfactant catabolism (GM-CSF recep-
tor), or transcription factors important for surfactant pro-
duction (TTF1) or lung development (Fox F1) may cause
pediatric diffuse lung disease [116]. This is an heteroge-
neous group of uncommon disorders with impaired gas
exchange and diffuse infiltrates at chest imaging [117].
Montella et al. [118] report on a 3-years-old boy with dry
cough, progressive hypoxemia, dyspnea and bilateral
ground glass opacities at chest high-resolution computed
tomography (HRCT), in whom lung histology strongly
suggested a surfactant disorder, but no variants conclu-
sively classified as pathogenic in genes encoding surfactant
proteins or transcription factors important for surfactant
production were found. Pulse intravenous high-dose
methylprednisolone, oral hydroxychloroquine and azithro-
mycin were started as treatment, leading to gradual wean-
ing from oxygen and to improvement of cough and
dyspnea. Six months later, steroids and oxygen were
stopped and a substantial improvement of exercise toler-
ance versus pre-treatment test was observed. Currently,
the subject is 6 years-old, adherence to treatment is satis-
factory, with no side effects. Repeated daily oxygen trans-
cutaneous saturation showed values not lower than 98 %
at room air, with median overnight values of 96 % (min
74 %, max 99 %), while chest HRCT was unmodified.
The authors confirm that in children with suspected
surfactant dysfunction, genetic testing is strongly recom-
mended because it can provide a definitive diagnosis but
when causative mutations are not found, lung biopsy
with consistent histology may help physicians to address
the definitive diagnosis.
Respiratory Syncytial Virus (RSV) is by far the pathogen
responsible for most of the airway infections in children
under age 2 years. RSV bronchiolitis is a leading cause of
severe respiratory disease that requires hospitalization
and, in some cases, intensive care [119]. Quinonez et al.
[120] pointed out important issues in the management of
bronchiolitis, Pulse oximetry potentially overdiagnoses
hypoxemia and increase hospital admission and length of
stay [121]. Another point is that infants with bronchiolitis
should be provided with antipyretics, intravenous hydra-
tion, oxygen when necessary, and salbutamol should be
given to assess its efficacy. Finally, continuous treatment
with epinephrine or saline may increase length of hospital
stay and oxygen requirement when compared with “on-
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demand” treatments [122]. Infection can be consistently
prevented by the application of environmental, hygienic
and sanitary measures to minimize the viral diffusion
[123]. Recommendations drafted by the Italian Society of
Neonatology concerning prophylaxis of RSV infection
with palivizumab, a humanized monoclonal antibody that
blocks the viral replication during the epidemic season to
children at high risk have been revised in 2015 through
the update of epidemiological data [124]. Lanari et al.
[125] evaluated the risk factors for hospitalization due to
bronchiolitis during the first year of life in children born
at different gestational ages in Italy. The study population
consisted of 2314 newborns, of which 2210 (95.5 %) had a
1 year follow-up and were included in the analysis, while
the remaining 120 cases (5.4 %) were hospitalized during
the first year of life for bronchiolitis. Children born at 33–
34 weeks gestational age had a higher hospitalization rate
compared to other groups. Male gender, prenatal exposure
to maternal smoking, neonatal surfactant therapy, having
siblings aged less than 10 years, living in crowded condi-
tions and being exposed to epidemic season during the
first 3 months of life were identified as risk factors for high
rate of hospitalization for bronchiolitis. This confirms that
individual characteristics and exposure to environmental
factors play an important role in determining the risk of
severe infection and hospitalization, independently from
preterm birth. The analysis of the weight of each risk fac-
tor allows defining accurately the risk for bronchiolitis
hospitalization for any infant during the first year of life
and letting authors to conclude that indications of palivi-
zumab should be individually “tailored”.
Conclusions
This was an exciting year for pediatric research. This
review provides novel information with regard to patho-
physiology, clinical aspects, prevention and management
of common diseases in childhood. Several Position state-
ment of scientific societies on different issues including
nutrition and hyperbilirubinemia in newborns were
made available. New data on rare diseases, such as
disorder of surfactant metabolism, and 48,XXXY/
49,XXXXY mosaicism may improve their understanding.
Overall, these advances can improve diagnosis and treat-
ment of pediatric diseases and offer comprehensions on
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